Onapgo (Apomorphine Hydrochloride) for Parkinson's Disease

Overview
Onapgo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. It is prescribed to individuals who experience “off” episodes, during which their regular Parkinson’s medication does not adequately control symptoms. Onapgo is also known by its drug name, apomorphine hydrochloride.

As a dopaminergic agonist, Onapgo stimulates dopamine receptors in the brain, helping to improve motor function in people with Parkinson’s disease. It is thought to work by mimicking the effects of dopamine, a neurotransmitter that is deficient in individuals with this condition.

How do I take it?
Prescribing information states that Onapgo is administered as a continuous subcutaneous (under the skin) infusion. Treatment typically begins with an initial continuous dosage for up to 16 hours per day. Additional extra doses may be given as needed, with at least three hours between doses and a maximum of three extra doses per day. A health care provider may adjust the dosage based on response and tolerability. Onapgo should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Onapgo include infusion site nodules (small lumps under the skin), nausea, excessive sleepiness, infusion site discoloration, dyskinesia (involuntary movements), headache, and insomnia.

Rare but serious side effects may include blood clots, which can lead to pulmonary embolism (a blockage in the lungs), severe nausea and vomiting, sudden sleep episodes, low blood pressure, fainting, and an increased risk of falls. Onapgo may cause infusion site reactions, including infections. Some individuals may experience hallucinations, psychotic-like behavior, or worsening dyskinesia. Hemolytic anemia (a condition where red blood cells are destroyed faster than they can be made) has been reported. Impulse control disorders, such as compulsive gambling or binge-eating, may occur. Serious heart-related effects, including cardiac events and QTc prolongation (a heart rhythm disorder that can lead to sudden death), have been observed.

For more information about this treatment, visit:

Highlights of Prescribing Information: Onapgo (Apomorphine Hydrochloride) Injection, for Subcutaneous Use — DailyMed

FDA Approves Onapgo — Drugs.com